Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Witnesses tell Joint Economic Committee statutory hurdles slow biosimilar competition; panel weighs impact of lower-priced obesity drugs
Summary
Panelists told the Joint Economic Committee that statutory complexity on biologics and incentives in clinical trials have slowed biosimilar competition; speakers also discussed oral GLP‑1 tablets priced near $149 per month and the potential effects on Medicaid and chronic‑disease spending.
At a Joint Economic Committee hearing, participants argued that statutory and regulatory frameworks are a major reason biosimilar competition has lagged, and they debated how new obesity drugs could alter chronic‑disease spending.
Speaker 2 identified Title VII of the Affordable Care Act—the Biologics Price Competition and Innovation Act of 2009—as having provisions that make it harder to develop and…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
